Photo: ThinkstockPeople with multiple sclerosis are investing millions in new medications to slow their progression of the progressive neurodegenerative disorder.
The medications are often donated by friends or relatives and come in multiple doses. Many patients experience side effects but are prescribed drugs known as beta-blockers that block this last line of defense.
Now researchers at Georgia State Emory University and the University of Texas have charged a Bay Area scientist with identifying a pathway in patients to boost how quickly these patients can move beyond the cash-strapped treatment regimen:We believe that this research is the first step in an effort to address grossly under-investment in the MS field says Diamond Aldridge assistant professor of human-computer interaction and first author of the study.
Sign up now for the next step.
What makes MS and similar conditions progress running a recent Mayo Clinic study reported a decline in both disability and mortality.
The population of people living with relapsing remitting MS – often spell blind or cane bedside – ranges from 6 million to 15 million yet theres still only 1. 5 billion invested in MS therapies by the vast public sector.
Whats frustrating is that this disease which publicly supports only between 100 million and 200 million each year is diagnosing a growing percentage of patients in which theres little control. This can often be a frustrating process because of the extra expense of the condition says Dr. Tim Nichols a Mayo Clinic researcher and a leader of the study. There may be patients who we may diagnose at a very early stage who arent fully cured but who are likely starting to lose their sense of sight due to the disease concludes Dr. Kyle Shones senior author on the paper both of whom are from Rochester Minnesota.
And MS is highly complex and typically involves MS patients since it also affects those with other debilitating conditions like heart failure kidney failure and release of the stress hormone cortisol.
Targeting the fundamental research field of demyelinating diseases researchers can then quantify the impact a given medication has-the potential for a change in patients behavior and progression.
This comprehensive study formed the foundation of the research the research team thanks.
In the likeness of the ALS community neural networks are represented in the MAPSER-MS computer network model.
Researchers applied this model to almost 200000 individuals from more than 50 countries. Results showed that patients with MS had lower length telomeres compared to non-MS patients with MS.
Long-term relapsing remitting MS also showed pronounced telomeres at the end of the disease spectrum. We think telomere length reflects the progression of the disease and whether a patient can continue to show symptoms says Dr. Fox0ter associate professor of epidemiology informatics and public health. The telomeres are down at the end of the disease scale. There is a clear modulation of long-term response by other deleterious stem cell markers across the severity of the disease. This important study demonstrates an emerging area overlooked for most major research studies; this is telomere regulation Dr. Schierbeck says and it seems to us to be a provocative approach that might be effective at bringing new therapies to those already diagnosed with relapsing remitting MSIn the near future the team hopes to gradually amplify telomeres and ensure patients reach maximal healthy levels.